Utility of Percutaneous Meckel's Cave Methylprednisolone/Bupivacaine Injection for Patients With Refractory Trigeminal Neuralgia With Concomitant Continuous Pain

Le résumé fourni par la source

BACKGROUND AND OBJECTIVES: Patients with trigeminal neuralgia (TN) with concomitant continuous pain constitute a challenging population to treat. Lesioning procedures are associated with high rates of neuropathic pain deterioration. Meckel's cave methylprednisolone/bupivacaine injections may afford pain control in this subset of patients with low rates of neuropathic pain deterioration. Our aim was to identify predictors of pain response after methylprednisolone/bupivacaine injections in patients with medically refractory TN with concomitant continuous pain. METHODS: A retrospective analysis of percutaneous methylprednisolone/bupivacaine injections for TN with concomitant continuous pain from 2020 to 2024 with a minimum of 1-year follow-up at a single institution was conducted. Demographics and operative data were collected. The primary outcomes were immediate (at first follow-up) and long-term (at last follow-up) pain relief. Univariate and multivariable Cox proportional hazards regression analysis and Kaplan-Meier survival analysis assessed prognostic factors for immediate and long-term pain relief. RESULTS: A total of 42 patients underwent 54 percutaneous methylprednisolone/bupivacaine injections. No procedures were performed in the setting of active neurovascular compression. Dull pain was the predominant pain component in 55.6% and the minor component in 44.4% of cases. The immediate pain relief rate was 78.4%. On multivariable analysis at the first follow-up, predominantly dull pain predicted improved immediate pain relief (hazard ratio [HR]: 0.26; 95% CI [0.08-0.91]; P = .04), whereas age ≥61 years was associated with a higher risk of persistent immediate pain (HR: 4.93; 95% CI [1.05-23.1]; P = .04). The long-term pain relief rate was 35.2%, resulting in a median pain relief duration of 19.9 months. On multivariable analysis at the last follow-up, only repeat injections were associated with higher risk of inadequate long-term pain relief (HR: 2.84; 95% CI [1.17-6.86]; P = .02). Postoperative transient hypoesthesia was reported in 12.9% of cases. Importantly, no patients had deterioration of the neuropathic pain component. CONCLUSION: Percutaneous methylprednisolone/bupivacaine injections provide effective immediate pain relief for patients with TN with concomitant continuous pain with minimal risk of deteriorating neuropathic symptoms.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.